Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 11OTHER_GOV 2NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2Other hematologic neoplasm 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 1461Pancreatic Neoplasms 832Stomach Neoplasms 692Carcinoma, Hepatocellular 647Carcinoma, Non-Small-Cell Lung 540Neoplasms 459Breast Neoplasms 369Ovarian Neoplasms 338Neoplasm Metastasis 336Colonic Neoplasms 331Esophageal Neoplasms 297Liver Neoplasms 265Melanoma 255Lung Neoplasms 245Squamous Cell Carcinoma of Head and Neck 210Cholangiocarcinoma 180Carcinoma, Renal Cell 180Prostatic Neoplasms 175Head and Neck Neoplasms 172Triple Negative Breast Neoplasms 162Endometrial Neoplasms 160Rectal Neoplasms 159Uterine Cervical Neoplasms 155Gastrointestinal Neoplasms 142Urinary Bladder Neoplasms 139Biliary Tract Neoplasms 135Gastrointestinal Stromal Tumors 108Sarcoma 104Esophageal Squamous Cell Carcinoma 102Small Cell Lung Carcinoma 95

Interventions

uridine triacetate 1Gemcitabine 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Drug-Related Side Effects and Adverse Reactions × Gastrointestinal × Clear all
NCT00024427 2012-06-28

Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer

Wellstat Therapeutics

Phase 3 Completed
250 enrolled
Gastrointestinal

Pancreatic Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡